enGene（NASDAQ:ENGN）交易量大幅增加 - 仍然值得购买吗？
enGene Holdings Inc. (NASDAQ:ENGN) experienced a 16% increase in trading volume, with 194,725 shares traded. The stock price rose from $8.38 to $9.09. Analysts have set new price targets, with UBS raising its target from $4.00 to $10.00, and Citizens Jmp increasing it from $18.00 to $21.00. Raymond James upgraded the stock to a "strong-buy" with a $27.00 target. The average rating is "Moderate Buy" with a consensus target of $22.38. enGene focuses on gene-based therapeutics for oncology, utilizing its EDV platform for targeted delivery.
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) saw strong trading volume on Wednesday . 194,725 shares traded hands during trading, an increase of 16% from the previous session's volume of 168,385 shares.The stock last traded at $9.09 and had previously closed at $8.38.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ENGN. UBS Group upped their target price on shares of enGene from $4.00 to $10.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 12th. Citizens Jmp boosted their target price on enGene from $18.00 to $21.00 and gave the stock a "market outperform" rating in a research report on Wednesday, November 12th. Raymond James Financial upgraded enGene from an "outperform" rating to a "strong-buy" rating and set a $27.00 price target on the stock in a research note on Tuesday, November 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of enGene in a research note on Friday. Finally, Citigroup reaffirmed a "market outperform" rating on shares of enGene in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $22.38.
Read Our Latest Research Report on enGene
enGene Price Performance
The firm has a 50-day simple moving average of $8.16 and a 200-day simple moving average of $6.42. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The firm has a market cap of $604.25 million, a P/E ratio of -3.99 and a beta of -0.29.
enGene (NASDAQ:ENGN - Get Free Report) last released its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). As a group, analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current year.
Hedge Funds Weigh In On enGene
Several institutional investors and hedge funds have recently modified their holdings of ENGN. Cresset Asset Management LLC acquired a new stake in enGene during the second quarter worth about $36,000. Paloma Partners Management Co acquired a new stake in shares of enGene during the 2nd quarter worth approximately $38,000. PFS Partners LLC purchased a new position in shares of enGene during the 3rd quarter valued at approximately $61,000. Raymond James Financial Inc. increased its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock valued at $68,000 after purchasing an additional 7,932 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in shares of enGene in the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 64.16% of the company's stock.
About enGene
(Get Free Report)enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.
Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.
Recommended Stories
- Five stocks we like better than enGene
- Punch these codes into your ordinary brokerage account
- Do not delete, read immediately
- More than 2 million ounces defined - and still early in their story
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- What Expenses Can Be Deducted From Capital Gains Tax?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in enGene Right Now?
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
